Non-Alcoholic Fatty Liver Disease

Metabolic Diseases
10
Pipeline Programs
10
Companies
15
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
2
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Madrigal Pharmaceuticals
REZDIFFRAApproved
resmetirom
Madrigal Pharmaceuticals
Thyroid Hormone Receptor beta Agonist [EPC]oral2024

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Madrigal Pharmaceuticals
Madrigal PharmaceuticalsWEST CONSHOHOCKEN, PA
1 program
1
1
ResmetiromPhase 31 trial
Active Trials
NCT04951219Active Not Recruiting1,000Est. Apr 2026
Celltrion
CelltrionKorea - Incheon
1 program
1
GODEXPhase 31 trial
Active Trials
NCT06152991Enrolling By InvitationEst. Feb 2027
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
2
1
BI 1467335Phase 21 trial
BI 3006337Phase 11 trial
Dabigatran EtexilatePhase 11 trial
Active Trials
NCT05970640Completed64Est. Nov 2024
NCT03143166Completed36Est. Aug 2017
NCT03166735Completed114Est. Jun 2019
Rivus Pharmaceuticals
Rivus PharmaceuticalsVA - Charlottesville
1 program
1
HU6Phase 21 trial
Active Trials
NCT05979779Active Not RecruitingEst. Jun 2025
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs
1
NNC0194-0499Phase 11 trial
GlucagonN/A1 trial
MR spectroscopy of the liverN/A1 trial
Active Trials
NCT04859322Completed20Est. Dec 2021
NCT03866421Terminated3Est. Mar 2022
NCT05742919Completed24Est. Jun 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD7503 InterventionPhase 11 trial
Active Trials
NCT05560607Completed19Est. Feb 2024
Novartis
NovartisBASEL, Switzerland
1 program
1
LJN452Phase 11 trial
Active Trials
NCT03681457Completed42Est. Sep 2019
Pfizer
PfizerNEW YORK, NY
2 programs
Magnetic Resonance ElastographyN/A1 trial
Weight lossN/A1 trial
Active Trials
NCT03674528Completed152Est. Jun 2024
NCT01104220Active Not Recruiting144Est. Dec 2026
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
Dietary interventionN/A1 trial
Active Trials
NCT04400864Unknown60Est. May 2021
One Biosciences
One BiosciencesFrance - Paris
1 program
GanweiN/A1 trial
Active Trials
NCT06244550CompletedEst. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
CelltrionGODEX
Madrigal PharmaceuticalsResmetirom
Rivus PharmaceuticalsHU6
Boehringer IngelheimBI 1467335
Boehringer IngelheimBI 3006337
Novo NordiskNNC0194-0499
AstraZenecaAZD7503 Intervention
NovartisLJN452
Boehringer IngelheimDabigatran Etexilate
One BiosciencesGanwei
Novo NordiskGlucagon
Jerusalem PharmaceuticalsDietary intervention
Novo NordiskMR spectroscopy of the liver
PfizerMagnetic Resonance Elastography
PfizerWeight loss

Clinical Trials (15)

Total enrollment: 1,678 patients across 15 trials

NCT06152991CelltrionGODEX

Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy

Start: Sep 2023Est. completion: Feb 2027
Phase 3Enrolling By Invitation
NCT04951219Madrigal PharmaceuticalsResmetirom

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Start: Jul 2021Est. completion: Apr 20261,000 patients
Phase 3Active Not Recruiting
NCT05979779Rivus PharmaceuticalsHU6

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Start: Sep 2023Est. completion: Jun 2025
Phase 2Active Not Recruiting
NCT03166735Boehringer IngelheimBI 1467335

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Start: Jun 2017Est. completion: Jun 2019114 patients
Phase 2Completed
NCT05970640Boehringer IngelheimBI 3006337

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Start: Aug 2023Est. completion: Nov 202464 patients
Phase 1Completed
NCT05742919Novo NordiskNNC0194-0499

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Start: Feb 2023Est. completion: Jun 202324 patients
Phase 1Completed
NCT05560607AstraZenecaAZD7503 Intervention

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

Start: Aug 2022Est. completion: Feb 202419 patients
Phase 1Completed
NCT03681457NovartisLJN452

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Start: Sep 2018Est. completion: Sep 201942 patients
Phase 1Completed
NCT03143166Boehringer IngelheimDabigatran Etexilate

Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan

Start: May 2017Est. completion: Aug 201736 patients
Phase 1Completed
NCT06244550One BiosciencesGanwei

Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors

Start: Sep 2021Est. completion: Jun 2023
N/ACompleted
NCT04859322Novo NordiskGlucagon

The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover

Start: Feb 2021Est. completion: Dec 202120 patients
N/ACompleted
NCT04400864Jerusalem PharmaceuticalsDietary intervention

Mediterranean Diet Versus Paleolithic Diet for the Treatment of Non Alcohlic Fatty Liver Disease

Start: Dec 2019Est. completion: May 202160 patients
N/AUnknown
NCT03866421Novo NordiskMR spectroscopy of the liver

NAFLD Among Patients With Chronic Kidney Disease and the Effect of Kidney Transplantation

Start: May 2019Est. completion: Mar 20223 patients
N/ATerminated
NCT03674528PfizerMagnetic Resonance Elastography

Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

Start: May 2018Est. completion: Jun 2024152 patients
N/ACompleted
NCT01104220PfizerWeight loss

Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

Start: Apr 2010Est. completion: Dec 2026144 patients
N/AActive Not Recruiting

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
20h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Senior Specialist, Quality Management Systems

Crinetics Pharmaceuticals
San Diego, CA
4d ago
$91K - $114K/yr

Director, Quality Systems, Project Management, QRM, RS

Crinetics Pharmaceuticals
US California
4d ago
$178K - $223K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
10 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)